3104 Background: Institutional series suggest specific patient subgroups; female, Asian, non-smokers, respond preferentially to gefitinib. Vancouver, BC, has a large Asian population and therefore is an ideal location to study this differential effect. We performed a retrospective analysis of patients treated with single agent gefinitib to determine if our experience reflects this observation. Methods: Between April 2002 and August 2003, 31 patients were treated with gefitinib. Pathology, radiology, laboratory investigations and clinical records were reviewed. Partial radiologic response was defined as per SWOG response criteria. Symptom responses were subjectively evaluated from chart review. Tumor markers assessed included CEA, Ca 15.3, Ca 19–9 and Ca 125. Results: Baseline characteristics at diagnosis; 61% Caucasian, 39% Asian, male 45%, smokers 55%, non-smokers 39%, ECOG 0/1 87%. The tumor histology: 55% adenocarcinoma, 19% bronchoalveolar variant, 6.5% large cell, 3% squamous, 16.5% other. Median treatment length was 2 months. On radiologic review, 6 patients had a response, 13 had stable disease, 9 progressed, and 3 unknown. Fourteen patients reported improved symptoms, 6 had no change, and 9 had symptom progression. Tumor marker data was available in 18 patients: 7 had decrease in marker values, 4 had marker stabilization, and 7 had an increase. Toxicity was minimal; 1 patient had grade 3 hepatotoxicity that resolved with treatment cessation. There were 5 Asian female non-smokers; 2 had a response, 2 had stable disease and 1 progressed. Of the 6 radiological responders, 5 had ECOG 0/1, 4 were female, 5 non-smokers, 4 adenocarcinoma and 2 bronchoalveolar variant. A multivariate analysis of radiologic responders and those with stable disease is underway. Conclusions: At the BCCA, in a select number of patients with advanced NSCLC, gefitinib demonstrated clinical and radiologic anti-tumor benefit with minimal side effects. The molecular basis of the improved response rate observed in the subset of female, Asian, non-smokers with adenocarcinoma or bronchoalveolar variant warrants further exploration. No significant financial relationships to disclose.
Read full abstract